Opus Genetics Management

Management criteria checks 2/4

Opus Genetics' CEO is George Magrath, appointed in Nov 2023, has a tenure of 2.67 years. total yearly compensation is $1.49M, comprised of 40% salary and 60% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €2.28M. The average tenure of the management team and the board of directors is 2.5 years and 4.2 years respectively.

Key information

George Magrath

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	40.04%
CEO tenure	2.7yrs
CEO ownership	1.0%
Management average tenure	2.5yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has George Magrath's remuneration changed compared to Opus Genetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$107m
Dec 31 2025	US$1m	US$598k	-US$50m
Sep 30 2025	n/a	n/a	-US$68m
Jun 30 2025	n/a	n/a	-US$58m
Mar 31 2025	n/a	n/a	-US$59m
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

Compensation vs Market: George's total compensation ($USD1.49M) is above average for companies of similar size in the German market ($USD886.30K).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.

CEO

George Magrath (41 yo)

2.7yrs

Tenure

US$1,493,383

Compensation

Dr. George Magrath, MD, MBA, MS, serves as Chief Executive Officer & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
George Magrath	CEO & Director	2.7yrs	US$1.49m	1.02% € 2.3m
Benjamin Yerxa	President & Director	1.8yrs	no data	0.86% € 1.9m
Joseph Schachle	Chief Operating Officer	2.7yrs	US$718.41k	0.027% € 60.5k
Ashwath Jayagopal	Chief Scientific & Development Officer	2.4yrs	US$764.85k	0.069% € 155.4k
Robert Gagnon	CFO & Principal Accounting Officer	less than a year	no data	0.72% € 1.6m
Chris Ernst	Chief Technology Officer	no data	no data	no data
Jenny Kobin	Investor Relations Officer	no data	no data	no data
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.14% € 318.7k
Amy Zaremba Rabourn	Head of Financial Quality Assurance	no data	US$789.92k	0.056% € 125.4k
Bindu Manne	Head of Market Development & Commercialization	4.5yrs	no data	no data
Sally Tucker	Chief Medical Officer & Senior Vice President of Clinical Development	no data	no data	no data
Sarah Tuller	Chief Regulatory Officer	no data	no data	no data

2.5yrs

Average Tenure

52yo

Average Age

Experienced Management: R3X1's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
George Magrath	CEO & Director	2.7yrs	US$1.49m	1.02% € 2.3m
Benjamin Yerxa	President & Director	1.8yrs	no data	0.86% € 1.9m
James S. Manuso	Independent Director	5.7yrs	US$188.92k	0.35% € 793.6k
Adrienne Graves	Independent Director	1.8yrs	US$171.44k	0.12% € 279.4k
David Boyer	Member of Medical Advisory Board	no data	no data	no data
Richard Rodgers	Independent Director	5.7yrs	US$189.45k	0.39% € 863.2k
Susan Benton	Independent Director	5.7yrs	US$180.14k	0.27% € 594.7k
Cameron Gallagher	Independent Chairman	5.7yrs	US$295.97k	2.39% € 5.3m
Sean Ainsworth	Lead Independent Director	5.7yrs	US$210.14k	0.36% € 805.4k
Jean Bennett	Director	1.8yrs	US$168.50k	0.28% € 635.6k
Arshad Khanani	Member of Medical Advisory Board	2.3yrs	no data	no data
Mark Pennesi	Member of Medical Advisory Board	no data	no data	no data

4.2yrs

Average Tenure

59.5yo

Average Age

Experienced Board: R3X1's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/27 06:15
End of Day Share Price	2026/07/27 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Opus Genetics, Inc. is covered by 18 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Opus Genetics Provides Update On OPGx-BEST1 Program With Detailed Timeline For OPGx-BEST1 Results

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-Lca5 in Lca5-Associated Inherited Retinal Disease

New major risk - Shareholder dilution

High number of new directors

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Third quarter 2024 earnings released: US$0.29 loss per share (vs US$0.26 profit in 3Q 2023)

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.28 loss in 1Q 2023)

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

New minor risk - Profitability

Full year 2023 earnings released: US$0.46 loss per share (vs US$0.90 profit in FY 2022)

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 15%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 15%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Investor sentiment improves as stock rises 16%

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 24%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA